Literature DB >> 238365

Minoxidil--haemodynamic and clinical experiences with a new peripheral vasodilator.

R Sannerstedt, L Brorson, G Berglund, L Werkö.   

Abstract

Minoxidil, a new peripheral vasodilator, given orally to hypertensive men in single doses of 5-25 mg, produced no haemodynamic changes within one hour after administration. After repeated oral doses within 24 hours to a total of 15-45 mg and after 10 mg t.i.d. orally for one week, moderate decreases in BP were seen concomitant with tendencies to increased heart rate and cardiac output. Clinically, oral minoxidil 10-50 mg daily in combination with diuretics and adrenergic beta-receptor blocking agents achieved an improved BP control in five patients with sustained arterial hypertension and unsatisfactory response to previous treatment. However, in four of the five patients minoxidil had to be withdrawn because of side-effects. It is concluded that minoxidil, producing a hypotensive effect of slow onset, may find a place as a therapeutic addition to symptomatic patients with severe and therapy-resistant hypertensive cardiovascular disease, provided adequate measures are taken to counteract side-effects, especially water retention and development of oedemas.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 238365     DOI: 10.1111/j.0954-6820.1975.tb04941.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  3 in total

1.  Clinical and haemodynamic effects of minoxidil in refractory hypertension.

Authors:  R Zacest; D B Frewin; M A Robinson; L L Wilson; J R Lawrence; A R Clarkson; B Jackson
Journal:  Drugs       Date:  1976       Impact factor: 9.546

Review 2.  Minoxidil: a review of its pharmacological properties and therapeutic use.

Authors:  V M Campese
Journal:  Drugs       Date:  1981-10       Impact factor: 9.546

3.  Antihypertensive effects of a novel peripheral vasodilator, Ro 12-4713.

Authors:  D Chu; G Cocco; C Strozzi; R Vallini; M Nonato; R Amrein
Journal:  Eur J Clin Pharmacol       Date:  1981-03       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.